Women’s health company Evvy has raised a $40 million Series B led by Catalio Capital Management as it expands from at-home vaginal microbiome testing into fertility research, artificial intelligence and clinical care. Founded in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro, Evvy touts its test as the only at-home CLIA-certified and CLEP-certified metagenomic next-generation sequencing, or mNGS, test for analyzing vaginal microbes with a single swab. The company says it serves more than 100,000 U.S. patients and works with 3,000 practitioners. Evvy’s platform processes mailed-in samples, sends results to registered clinicians for review and posts diagnoses, interpretations and next steps in patients’ health portals. The company has produced 15 peer-reviewed publications and abstracts, identified novel bacterial-vaginosis subtypes and catalogued hundreds of previously unrecorded vaginal microbiome genomes. Its research is now examining links between vaginal microbiomes and infertility, gynecological cancer, preterm birth, IVF success and recurrent pregnancy loss. Evvy also launched EvvyAI in May to provide real-time vaginal-health guidance and direct users to clinicians when expert review is needed. The company says its longer-term goal is to build a biological dataset connecting microbiome signals, symptoms, interventions and outcomes, potentially supporting more data-rich care for women.